Component

Human alpha1 homomeric glycine receptor

Context-specific entity; species, compartment and exposure are stated on each claim.

4 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Applied taurine activated recombinant human alpha1 homomeric glycine receptors in oocytes and HEK293 cells; its potency and efficacy varied with the experimental receptor response.

    Taurine → Human alpha1 homomeric glycine receptor source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary abstract
    experimental_model
    Human receptor expressed in Xenopus oocytes or human cells; electrophysiology.
    limitations
    Not a clinical sedative effect; chloride gradient and receptor composition shape cellular response.
    nutrient_topic
    Taurine collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Taurine
    plain_language
    Taurine can activate a receptor named for glycine.
    primary_references
    Activation of human alpha1 and alpha2 homomeric glycine receptors by taurine and GABA. · 2001 · https://pubmed.ncbi.nlm.nih.gov/11559772/ · DOI 10.1111/j.1469-7793.2001.t01-1-00741.x

    Taurine: synthesis, transport, mitochondrial decoding and nutrient interactions (2026-09-19) · lines 417–423

    AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Human receptor expressed in Xenopus oocytes or human cells; electrophysiology. · source_derived_draft · unverified_draft

    ## taurine-glycine-receptor-alpha1 Taurine can activate a receptor named for glycine. Applied taurine activated recombinant human alpha1 homomeric glycine receptors in oocytes and HEK293 cells; its potency and efficacy varied with the experimental receptor response. Model: Human receptor expressed in Xenopus oocytes or human cells; electrophysiology. Limitations: Not a clinical sedative effect; chloride gradient and receptor composition shape cellular response. Evidence access: Primary abstract Activation of human alpha1 and alpha2 homomeric glycine receptors by taurine and GABA. · 2001 · https://pubmed.ncbi.nlm.nih.gov/11559772/ · DOI 10.1111/j.1469-7793.2001.t01-1-00741.x
    Complete structured claim and evidence

  2. At saturating 30 mM agonist, human alpha1 glycine-receptor activation rose faster with glycine than beta-alanine or taurine, and glycine responses decayed more slowly after removal.

    Glycine → Human alpha1 homomeric glycine receptor source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary abstract
    experimental_model
    Human recombinant receptor comparison using high agonist concentrations.
    limitations
    Not equivalent to relative sedative potency after oral intake.
    nutrient_topic
    Glycine collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · Glycine
    plain_language
    Related molecules activate the same receptor with different timing.
    primary_references
    Kinetic determinants of agonist action at the recombinant human glycine receptor. · 2003 · https://pubmed.ncbi.nlm.nih.gov/12679369/ · DOI 10.1113/jphysiol.2002.037796

    Glycine: supply, one-carbon allocation, receptors and cross-nutrient mechanisms (2026-09-19) · lines 202–208

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Human recombinant receptor comparison using high agonist concentrations. · source_derived_draft · unverified_draft

    ## glycine-glyr-ligand-kinetics Related molecules activate the same receptor with different timing. At saturating 30 mM agonist, human alpha1 glycine-receptor activation rose faster with glycine than beta-alanine or taurine, and glycine responses decayed more slowly after removal. Model: Human recombinant receptor comparison using high agonist concentrations. Limitations: Not equivalent to relative sedative potency after oral intake. Evidence access: Primary abstract Kinetic determinants of agonist action at the recombinant human glycine receptor. · 2003 · https://pubmed.ncbi.nlm.nih.gov/12679369/ · DOI 10.1113/jphysiol.2002.037796
    Complete structured claim and evidence

  3. Glycine opened recombinant human alpha1 homomeric glycine receptors in HEK293 cells; rapid-application and single-channel assays resolved activation kinetics.

    Glycine → Human alpha1 homomeric glycine receptor source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary abstract
    experimental_model
    Human alpha1 receptor, rapid agonist application and patch recording.
    limitations
    Homomeric experimental receptor differs from native heteromeric receptor mixtures; chloride gradient determines current consequences.
    nutrient_topic
    Glycine collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · Glycine
    plain_language
    Glycine can directly open a receptor channel.
    primary_references
    Kinetic determinants of agonist action at the recombinant human glycine receptor. · 2003 · https://pubmed.ncbi.nlm.nih.gov/12679369/ · DOI 10.1113/jphysiol.2002.037796

    Glycine: supply, one-carbon allocation, receptors and cross-nutrient mechanisms (2026-09-19) · lines 194–200

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Human alpha1 receptor, rapid agonist application and patch recording. · source_derived_draft · unverified_draft

    ## glycine-glyr-opening Glycine can directly open a receptor channel. Glycine opened recombinant human alpha1 homomeric glycine receptors in HEK293 cells; rapid-application and single-channel assays resolved activation kinetics. Model: Human alpha1 receptor, rapid agonist application and patch recording. Limitations: Homomeric experimental receptor differs from native heteromeric receptor mixtures; chloride gradient determines current consequences. Evidence access: Primary abstract Kinetic determinants of agonist action at the recombinant human glycine receptor. · 2003 · https://pubmed.ncbi.nlm.nih.gov/12679369/ · DOI 10.1113/jphysiol.2002.037796
    Complete structured claim and evidence

  4. Ivermectin irreversibly activated human alpha1 homomeric and alpha1beta heteromeric glycine receptors at concentrations at or above 0.03 micromolar, through a site that is not the glycine site.

    Ivermectin → Human alpha1 homomeric glycine receptor source_derived_draftungraded
    Experimental context and source evidence
    duration
    Acute and irreversible within the experiment
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    experimental_model
    Recombinant human alpha1 homomeric and alpha1beta heteromeric glycine receptors
    exposure
    0.03 micromolar potentiation and higher-concentration irreversible activation
    limitations
    Ivermectin-gated currents showed markedly reduced sensitivity to strychnine, picrotoxin and zinc, so the pharmacology of this activation differs from ordinary glycinergic transmission.
    organism
    Recombinant human alpha1 homomeric and alpha1beta heteromeric glycine receptors
    plain_language
    Ivermectin irreversibly activated human alpha1 homomeric and alpha1beta heteromeric glycine receptors at concentrations at or above 0.03 micromolar, through a site that is not the glycine site.
    primary_references
    Ivermectin, an unconventional agonist of the glycine receptor chloride channel. (2001). https://pubmed.ncbi.nlm.nih.gov/11278873/ DOI: 10.1074/jbc.M011264200
    route
    In vitro
    tissue
    Inhibitory chloride channel gating

    Ivermectin: mechanism of action across parasite, host barrier and mammalian targets (2026-09-22) · lines 112–121

    Original AI-assisted curation of sixteen primary studies resolved by PubMed title search and cross-checked against live PubMed metadata. Study-specific citations, concentrations, negative findings and limitations retained. Not publisher full text. · supports · · source_derived_draft · unverified_draft

    ## ivermectin-glycine-receptor-activation Ivermectin irreversibly activated human alpha1 homomeric and alpha1beta heteromeric glycine receptors at concentrations at or above 0.03 micromolar, through a site that is not the glycine site. Model/species: Recombinant human alpha1 homomeric and alpha1beta heteromeric glycine receptors Tissue/system: Inhibitory chloride channel gating Exposure: 0.03 micromolar potentiation and higher-concentration irreversible activation Route: In vitro Duration: Acute and irreversible within the experiment Limits: Ivermectin-gated currents showed markedly reduced sensitivity to strychnine, picrotoxin and zinc, so the pharmacology of this activation differs from ordinary glycinergic transmission. Primary reference: Ivermectin, an unconventional agonist of the glycine receptor chloride channel. (2001). https://pubmed.ncbi.nlm.nih.gov/11278873/ DOI: 10.1074/jbc.M011264200 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards